Patents Assigned to GUANGDONG RAYNOVENT BIOTECH CO., LTD.
  • Anti-influenza virus pyrimidine derivative
    Patent number: 11725009
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: August 15, 2023
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Crystal form and salt form of pyridoimidazole compound and preparation method therefor
    Patent number: 11535613
    Abstract: Disclosed are a crystal form and a salt form of a pyrazolopridine compound, and a preparation method therefor. Further included is the use of the crystal form in preparing anti-influenza virus drugs.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: December 27, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Jian Xiong, Xiaoxin Chen, Jingjing Wang, Zhuowei Liu, Kevin X Chen, Chengwu Liu, Cheng Xie, Chaofeng Long, Peng Li, Jian Li, Shuhui Chen
  • Amorphous pyrrolidine derivative as PPAR agonist and preparation method thereof
    Patent number: 11396493
    Abstract: The present invention relates to an amorphous pyrrolidine derivative as a PPAR agonist and a preparation method thereof.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 26, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Zhiliang Yuan, Zhigan Jiang, Haiying He, Xiao Zhang, Jiwen Xu, Weixiang Zhou, Jian Li, Shuhui Chen
  • Anti-influenza virus pyrimidine derivative
    Patent number: 11136319
    Abstract: The present invention discloses a class of anti-influenza virus compounds, and the use thereof in the preparation of a drug for treating diseases associated with influenza viruses. In particular, the present invention discloses a compound represented by formula (I) and a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: October 5, 2021
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Jian Xiong, Chaofeng Long, Jingjing Wang, Xiaoxin Chen, Kevin X Chen, Cheng Xie, Peng Li, Xuanjia Peng, Jian Li, Shuhui Chen
  • Crystal form and salt form of and preparation method for tyrosine kinase inhibitor
    Patent number: 10766862
    Abstract: Disclosed are a crystal form and a salt form of and a preparation method for a tyrosine kinase inhibitor.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: September 8, 2020
    Assignee: Guangdong Raynovent Biotech Co., Ltd.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Shuhui Chen, Jian Li
  • Tyrosine kinase inhibitor and pharmaceutical composition comprising same
    Patent number: 10654808
    Abstract: The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same.
    Type: Grant
    Filed: April 7, 2016
    Date of Patent: May 19, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Chaofeng Long, Zhengxia Chen, Xiaoxin Chen, Yang Zhang, Zhuowei Liu, Peng Li, Shuhui Chen, Guibai Liang, Cheng Xie, Zhengwei Li, Zhifei Fu, Guoping Hu, Jian Li
  • Hydroxyl purine compounds and use thereof
    Patent number: 10618898
    Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: April 14, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Linyun Wu, Xiaoxin Chen, Peng Zhang, Xing Liu, Li Zhang, Zhuowei Liu, Shuhui Chen, Chaofeng Long
  • Pyrrolidine derivatives as PPAR agonists
    Patent number: 10526320
    Abstract: The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: January 7, 2020
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Zhiliang Yuan, Chaofeng Long, Zhigan Jiang, Xiaoxin Chen, Haiying He, Xing Liu, Xiao Zhang, Zhiqiang Liu, Yan Wang, Leilei Gao, Zhen Gong, Jian Li, Shuhui Chen
  • Crystal form A of 7-(cyclopropylmethyl)-1-((()-4-hydroxy-4-methylcyclohexyl)methyl)-3-methyl-1H-purine-2,6-(3H,7H)-dione for treating liver diseases
    Patent number: 10399981
    Abstract: The invention discloses a crystal form A of a compound (I) and a preparation method thereof, and further discloses an application of the crystal form A as a PDE2 or TNF-? inhibitor.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: September 3, 2019
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Lingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Zheng Wang, Shuhui Chen, Lijuan Chen
  • Hydroxyl purine compounds and use thereof
    Patent number: 10278973
    Abstract: Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNF? inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: May 5, 2016
    Date of Patent: May 7, 2019
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Lingyun Wu, Xiaoxin Chen, Peng Zhang, Xing Liu, Li Zhang, Zhuowei Liu, Shuhui Chen, Chaofeng Long
  • Hydroxyl purine compounds and applications thereof
    Patent number: RE49128
    Abstract: Hydroxyl purine compounds represented by formula (I), tautomers or pharmaceutically acceptable salts thereof, and applications thereof as PDE2 or TNF-? inhibitors.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: July 12, 2022
    Assignee: GUANGDONG RAYNOVENT BIOTECH CO., LTD.
    Inventors: Lingyun Wu, Chaofeng Long, Peng Zhang, Xiaoxin Chen, Li Zhang, Zhuowei Liu, Jian Li, Shuhui Chen